Use of cordyceps sinensis MBF1 in preparation of Anti-radiation injury health product or drug

Abstract

Disclosed is use of Cordyceps sinensis MBF1 in the preparation of a health product or drug for preventing and / or treating radiation injury, particularly in the preparation of a health product or drug for preventing and / or treating intestinal radiation injury and / or hematopoietic radiation injury caused by ionizing radiation. Cordyceps sinensis MBF1 can significantly ameliorate symptoms caused by intestinal radiation injury, such as shortened colon length, small intestinal tissue injury, and elevated small intestinal inflammation level, ameliorate symptoms caused by hematopoietic radiation injury, such as reduced white blood cell count, reduced spleen index, and / or reduced thymus index, and can be used as a health product or drug for preventing and treating radiation injury, particularly intestinal radiation injury and / or hematopoietic radiation injury, thereby addressing the current lack of effective health products or drugs for the clinical treatment of intestinal radiation injury and / or hematopoietic radiation injury. In addition, the present disclosure provides a new idea and strategy for developing an anti-radiation injury health product or drug and demonstrates important scientific significance and clinical application value.

Description

Uses of Cordyceps sinensis MBF1 in the preparation of anti-radiation damage health products or drugs Technical Field

[0001] This invention belongs to the field of biomedicine technology. Specifically, this invention relates to the application of Cordyceps sinensis MBF1 in the preparation of anti-radiation damage health products or drugs. Background Technology

[0002] Ionizing radiation (IR) can have significant effects on the bone marrow hematopoietic system, gastrointestinal tract, and nervous system. The intestines, being rapidly regenerating tissue, are particularly sensitive to ionizing radiation. Systemic radiation damage (such as that caused by nuclear explosions or accidents) and localized radiotherapy for tumors in the abdominal and pelvic cavities can all cause damage to intestinal structure and function. Acute intestinal syndrome is a leading cause of death within the first week after exposure to high doses of radiation. Rapid and destructive damage to intestinal epithelial cells primarily leads to intestinal electrolyte imbalance, malabsorption, and translocation of intestinal pathogens, ultimately resulting in loss of intestinal function and a significantly increased risk of death.

[0003] In clinical practice, radiation-induced intestinal radiation injury is a common complication of radiotherapy for abdominal and pelvic tumors, severely limiting the intensity and efficacy of radiotherapy plans. Currently, there are no effective prevention and treatment methods for intestinal radiation injury, both domestically and internationally. Therefore, finding effective preventative health products or drugs for intestinal radiation injury is of great significance. In recent years, a series of compounds with radiation-protective effects, including aminothiols, natural antioxidants, hormone-based health products or drugs, and biological macromolecular preparations, have been researched and developed, including amifostine, cysteine, estrogen, and vitamins. However, most of these compounds do not have clear efficacy or excellent performance. To date, amifostine is the only FDA-approved clinical radioprotective agent for head and neck cancer patients, used to reduce the incidence of moderate to severe xerostomia. The main mechanism of action of amifostine is that, in the presence of a single-bonded SH group, its metabolite (WR1065) can scavenge oxygen free radicals generated by ionizing radiation, thereby preventing oxygen free radicals from damaging intracellular macromolecules. Nevertheless, because the effective dose of amifostine is close to the minimum toxic dose, increasing the dose may lead to significant adverse reactions and limit its widespread use.

[0004] Multiprotein Bridging Factor 1 (MBF1) is a highly conserved transcriptional coactivator that regulates transcriptional activation by linking the basal transcription factor TBP (TATAelement-binding protein) with specific activators such as FTZ-F1, bZIP, and GCN4. MBF1 is present in most archaea and all eukaryotes, and extensive research has shown its involvement in developmental processes and stress responses. In fungi, apart from limited work on *Saccharomyces cerevisiae*, MBF1 in other fungi remains largely unexplored. Summary of the Invention

[0005] In order to overcome the above-mentioned technical problems existing in the field, the purpose of this invention is to provide Cordyceps sinensis MBF1 as a health product or medicine for anti-radiation damage, and to provide an effective health product or medicine strategy for the field.

[0006] The present invention achieves the above-mentioned objective by adopting the following technical solution: The present invention provides the use of Cordyceps sinensis MBF1 (or water extract of Cordyceps sinensis fermentation powder or protein extract of water extract) in the preparation of products for the prevention and / or treatment of radiation damage.

[0007] Furthermore, the radiation damage is caused by ionizing radiation.

[0008] Furthermore, the ionizing radiation is ionizing radiation generated by tumor radiotherapy.

[0009] Furthermore, the ionizing radiation is gamma-ray radiation.

[0010] Furthermore, the radiation damage is intestinal radiation damage and / or hematopoietic system radiation damage.

[0011] Furthermore, the intestinal radiation injury has one or more of the following symptoms: shortened colon length, small intestinal tissue damage, and elevated level of small intestinal inflammation.

[0012] Furthermore, the radiation injury to the hematopoietic system has one or more of the following symptoms: decreased white blood cell count, decreased spleen index, and / or decreased thymus index.

[0013] Furthermore, the marker of small intestinal tissue damage is a decrease in the expression level of the small intestinal Occludin gene.

[0014] Furthermore, the elevated level of small intestinal inflammation includes an increase in the level of inflammatory immune factors.

[0015] Furthermore, the inflammatory immune factor is IL-6.

[0016] Furthermore, the amino acid sequence of the Cordyceps sinensis MBF1 includes SEQ ID NO: 1, or includes an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% homology with the sequence shown in SEQ ID NO: 1.

[0017] Furthermore, the amino acid sequence of the Cordyceps sinensis MBF1 is shown in SEQ ID NO: 1.

[0018] The Cordyceps sinensis fermented mycelium powder aqueous extract is obtained by alcohol extraction of Cordyceps sinensis fermented mycelium powder.

[0019] Furthermore, the extraction method of the water extract of Cordyceps sinensis fermented mycelium powder includes alcohol extraction of Cordyceps sinensis fermented mycelium powder followed by ultrasonication and centrifugation to obtain a precipitate, and then resuspending the precipitate followed by ultrasonication and centrifugation to obtain the supernatant.

[0020] The centrifugation time is 5-10 minutes, such as 5 minutes, 6 minutes, 7 minutes, 8 minutes, 9 minutes, or 10 minutes.

[0021] The centrifugal force is 10,000-14,000g, for example, 10,000g, 12,000g, 13,000g or 14,000g.

[0022] The protein extract of the aqueous extract is the total protein extracted from the aqueous extract of Cordyceps sinensis fermentation powder.

[0023] The extraction method for the protein extract from the aqueous extract includes adding solid ammonium sulfate to the aqueous extract until its saturation reaches 40%-80%, letting it stand on ice, and then centrifuging to obtain protein precipitate.

[0024] Furthermore, the extraction method also includes dissolving the protein precipitate, dialysis to remove ammonium sulfate, and then concentrating the precipitate to obtain the final product.

[0025] The settling time is 0.5-2 hours, for example, 0.5 hours, 1 hour, 1.5 hours or 2 hours.

[0026] The centrifugation temperature is 0-10℃, for example, 0℃, 1℃, 2℃, 3℃, 4℃, 5℃, 6℃, 7℃, 8℃, 9℃ or 10℃.

[0027] The centrifugal force is 10,000-14,000g, for example, 10,000g, 12,000g, 13,000g or 14,000g.

[0028] The centrifugation time is 20-40 min, for example, 20 min, 25 min, 30 min, 35 min or 40 min.

[0029] The dialysis was performed using a buffer solution, such as PBS.

[0030] The dialysis temperature is 0-10℃, for example, 0℃, 1℃, 2℃, 3℃, 4℃, 5℃, 6℃, 7℃, 8℃, 9℃ or 10℃.

[0031] The dialysis-retained substance has a molecular weight cutoff of 8000 Da.

[0032] The product in question is a health supplement or a medicine.

[0033] In another aspect, the present invention also provides the use of 4 mg to 8 mg (e.g., 4 mg, 5 mg, 6 mg, 7 mg or 8 mg) of Cordyceps sinensis MBF1 (aqueous extract of Cordyceps sinensis fermentation powder or protein extract of aqueous extract) in products for the prevention and / or treatment of radiation damage.

[0034] Furthermore, the unit dose of Cordyceps sinensis MBF1 is administered once daily.

[0035] Furthermore, the radiation damage is caused by ionizing radiation.

[0036] Furthermore, the ionizing radiation is ionizing radiation generated by tumor radiotherapy.

[0037] Furthermore, the ionizing radiation is gamma-ray radiation.

[0038] Furthermore, the radiation damage is intestinal radiation damage and / or hematopoietic system radiation damage.

[0039] Furthermore, the intestinal radiation injury has one or more of the following symptoms: shortened colon length, small intestinal tissue damage, and elevated level of small intestinal inflammation.

[0040] Furthermore, the marker of small intestinal tissue damage is a decrease in the expression level of the small intestinal Occludin gene.

[0041] Furthermore, the radiation injury to the hematopoietic system has one or more of the following symptoms: decreased white blood cell count, decreased spleen index, and / or decreased thymus index.

[0042] Furthermore, the elevated level of small intestinal inflammation includes an increase in the expression of inflammatory immune factors.

[0043] Furthermore, the inflammatory immune factor is IL-6.

[0044] The product in question is a health supplement or a medicine.

[0045] Furthermore, the amino acid sequence of the Cordyceps sinensis MBF1 includes SEQ ID NO: 1, or includes an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% homology with the sequence shown in SEQ ID NO: 1.

[0046] Furthermore, the amino acid sequence of the Cordyceps sinensis MBF1 is shown in SEQ ID NO: 1.

[0047] The Cordyceps sinensis fermented mycelium powder aqueous extract is obtained by alcohol extraction of Cordyceps sinensis fermented mycelium powder.

[0048] Furthermore, the extraction method of the water extract of Cordyceps sinensis fermented mycelium powder includes alcohol extraction of Cordyceps sinensis fermented mycelium powder followed by ultrasonication and centrifugation to obtain a precipitate, and then resuspending the precipitate followed by ultrasonication and centrifugation to obtain the supernatant.

[0049] The centrifugation time is 5-10 minutes, such as 5 minutes, 6 minutes, 7 minutes, 8 minutes, 9 minutes, or 10 minutes.

[0050] The centrifugal force is 10,000-14,000g, for example, 10,000g, 12,000g, 13,000g or 14,000g.

[0051] The protein extract of the aqueous extract is the total protein extracted from the aqueous extract of Cordyceps sinensis fermentation powder.

[0052] The extraction method for the protein extract from the aqueous extract includes adding solid ammonium sulfate to the aqueous extract until its saturation reaches 40%-80%, letting it stand on ice, and then centrifuging to obtain protein precipitate.

[0053] Furthermore, the extraction method also includes dissolving the protein precipitate, dialysis to remove ammonium sulfate, and then concentrating the precipitate to obtain the final product.

[0054] The settling time is 0.5-2 hours, for example, 0.5 hours, 1 hour, 1.5 hours or 2 hours.

[0055] The centrifugation temperature is 0-10℃, for example, 0℃, 1℃, 2℃, 3℃, 4℃, 5℃, 6℃, 7℃, 8℃, 9℃ or 10℃.

[0056] The centrifugal force is 10,000-14,000g, for example, 10,000g, 12,000g, 13,000g or 14,000g.

[0057] The centrifugation time is 20-40 min, for example, 20 min, 25 min, 30 min, 35 min or 40 min.

[0058] The dialysis was performed using a buffer solution, such as PBS.

[0059] The dialysis temperature is 0-10℃, for example, 0℃, 1℃, 2℃, 3℃, 4℃, 5℃, 6℃, 7℃, 8℃, 9℃ or 10℃.

[0060] The dialysis-retained substance has a molecular weight cutoff of 8000 Da.

[0061] Furthermore, 4mg to 8mg unit dose Cordyceps sinensis MBF1 refers to 4mg to 8mg of Cordyceps sinensis MBF1 prepared in unit dose form, including but not limited to tablets, capsules and / or pills.

[0062] In another aspect, the present invention provides the use of an aqueous extract of Cordyceps sinensis or Cordyceps sinensis fermentation powder or a protein extract thereof containing MBF1 in the preparation of products for the prevention and / or treatment of radiation damage.

[0063] The product in question is a health supplement or a medicine.

[0064] Furthermore, the radiation damage is intestinal radiation damage and / or hematopoietic system radiation damage.

[0065] In another aspect, the present invention also provides a method for preventing and / or treating radiation damage, the method comprising administering to a subject in need an effective amount of Cordyceps sinensis MBF1 or a water extract of Cordyceps sinensis containing MBF1 or a protein extract of a fermented Cordyceps sinensis powder or a water extract thereof.

[0066] Furthermore, the radiation damage is caused by ionizing radiation.

[0067] Furthermore, the ionizing radiation is ionizing radiation generated by tumor radiotherapy.

[0068] Furthermore, the ionizing radiation is gamma-ray radiation.

[0069] Furthermore, the radiation damage is intestinal radiation damage and / or hematopoietic system radiation damage.

[0070] Furthermore, the intestinal radiation injury has one or more of the following symptoms: shortened colon length, small intestinal tissue damage, and elevated level of small intestinal inflammation.

[0071] Furthermore, the marker of small intestinal tissue damage is a decrease in the expression level of the small intestinal Occludin gene.

[0072] Furthermore, the radiation injury to the hematopoietic system has one or more of the following symptoms: decreased white blood cell count, decreased spleen index, and / or decreased thymus index.

[0073] Furthermore, the elevated level of small intestinal inflammation includes an increase in the level of inflammatory immune factors.

[0074] Furthermore, the inflammatory immune factor is IL-6.

[0075] Furthermore, the amino acid sequence of the Cordyceps sinensis MBF1 includes SEQ ID NO: 1, or includes an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% homology with the sequence shown in SEQ ID NO: 1.

[0076] Furthermore, the amino acid sequence of the Cordyceps sinensis MBF1 is shown in SEQ ID NO: 1.

[0077] Furthermore, the method includes administering a unit dose of 4 mg to 8 mg of Cordyceps sinensis MBF1, or a water extract of Cordyceps sinensis containing MBF1, or a protein extract of a fermented Cordyceps sinensis powder, to a subject in need.

[0078] The Cordyceps sinensis fermented mycelium powder aqueous extract is obtained by alcohol extraction of Cordyceps sinensis fermented mycelium powder.

[0079] Furthermore, the extraction method of the water extract of Cordyceps sinensis fermented mycelium powder includes alcohol extraction of Cordyceps sinensis fermented mycelium powder followed by ultrasonication and centrifugation to obtain a precipitate, and then resuspending the precipitate followed by ultrasonication and centrifugation to obtain the supernatant.

[0080] The centrifugation time is 5-10 minutes, such as 5 minutes, 6 minutes, 7 minutes, 8 minutes, 9 minutes, or 10 minutes.

[0081] The centrifugal force is 10,000-14,000g, for example, 10,000g, 12,000g, 13,000g or 14,000g.

[0082] The protein extract of the aqueous extract is the total protein extracted from the aqueous extract of Cordyceps sinensis fermentation powder.

[0083] The extraction method for the protein extract from the aqueous extract includes adding solid ammonium sulfate to the aqueous extract until its saturation reaches 40%-80%, letting it stand on ice, and then centrifuging to obtain protein precipitate.

[0084] Furthermore, the extraction method also includes dissolving the protein precipitate, dialysis to remove ammonium sulfate, and then concentrating the precipitate to obtain the final product.

[0085] The settling time is 0.5-2 hours, for example, 0.5 hours, 1 hour, 1.5 hours or 2 hours.

[0086] The centrifugation temperature is 0-10℃, for example, 0℃, 1℃, 2℃, 3℃, 4℃, 5℃, 6℃, 7℃, 8℃, 9℃ or 10℃.

[0087] The centrifugal force is 10,000-14,000g, for example, 10,000g, 12,000g, 13,000g or 14,000g.

[0088] The centrifugation time is 20-40 min, for example, 20 min, 25 min, 30 min, 35 min or 40 min.

[0089] The dialysis was performed using a buffer solution, such as PBS.

[0090] The dialysis temperature is 0-10℃, for example, 0℃, 1℃, 2℃, 3℃, 4℃, 5℃, 6℃, 7℃, 8℃, 9℃ or 10℃.

[0091] The dialysis-retained substance has a molecular weight cutoff of 8000 Da.

[0092] Furthermore, the unit dose of Cordyceps sinensis MBF1 or Cordyceps sinensis containing MBF1 or Cordyceps sinensis fermentation powder aqueous extract or protein extract of aqueous extract is administered once daily.

[0093] The administration method can be gastrointestinal (e.g., oral) or non-gastrointestinal (e.g., intravenous, intramuscular, subcutaneous, intradermal, intra-organ, intranasal, intraocular, intravenous, intracerebral, intrathecal, transdermal, rectal, etc.) routes.

[0094] Compared to existing technologies, this invention offers the following advantages: For the first time, this invention discovers that Cordyceps sinensis MBF1, or Cordyceps sinensis containing MBF1, or a water extract of Cordyceps sinensis fermentation powder, or a protein extract of its water extract, can significantly improve symptoms caused by intestinal radiation injury, such as shortened colon length, small intestinal tissue damage, and elevated small intestinal inflammation levels. It also improves symptoms caused by radiation injury to the hematopoietic system, such as decreased white blood cell count, decreased spleen index, and / or decreased thymus index. This invention can serve as a preventative health product or drug for radiation injury, particularly intestinal radiation injury and / or hematopoietic system radiation injury, addressing the current lack of truly effective health products or drugs for the clinical treatment of intestinal radiation injury and / or hematopoietic system radiation injury. Furthermore, it provides new ideas and strategies for developing anti-radiation damage health products or drugs, possessing significant scientific and clinical application value. Attached Figure Description

[0095] Figure 1. Statistical results of white blood cell count in the blood of mice in each group after 21 days of drug administration in Example 1;

[0096] Figure 2. Spleen index detection results of mice in each group after 21 days of drug administration in Example 1;

[0097] Figure 3. Thymus index results of mice in each group after 21 days of drug administration in Example 1;

[0098] Figure 4. Statistical results of colon length in mice of each group after 14 days of drug administration in Example 2;

[0099] Figure 5. Results of relative expression of small intestinal integrity marker (Occludin) in mice of each group 14 days after administration in Example 2;

[0100] Figure 6. Results of IL-6 content detection in the small intestine of mice in each group after 14 days of drug administration in Example 2;

[0101] Figure 7. Statistical results of colon length in mice of each group after 14 days of drug administration in Example 3;

[0102] Figure 8. Results of relative expression of small intestinal integrity marker (Occludin) in mice of each group 14 days after administration in Example 3;

[0103] Figure 9. Results of IL-6 content detection in the small intestine of mice in each group after 14 days of drug administration in Example 3;

[0104] Figure 10 Six key Cordyceps sinensis MBF1 proteins involved in radiation protection;

[0105] Figure 11. Plasmid map of heterologous expression of T5AE42 protein in Escherichia coli;

[0106] Figure 12 shows the statistical results of colon length in mice of each group after 14 days of drug administration in Example 4;

[0107] Figure 13 shows the relative expression levels of the small intestine integrity marker (Occludin) in each group of mice 14 days after administration in Example 4.

[0108] Figure 14. Results of IL-6 content detection in the small intestine of mice in each group after 14 days of drug administration in Example 4;

[0109] Figure 15. Peptide identification by T5AE42 protein gel mass spectrometry. Detailed Implementation

[0110] The embodiments of the present invention are described in detail below. These embodiments are exemplary and are only used to explain the present invention, and should not be construed as limiting the present invention.

[0111] According to an embodiment of the present invention, Cordyceps sinensis is provided in the form of fermented Cordyceps sinensis mycelium powder.

[0112] In this text, the term "fermented Cordyceps sinensis mycelial powder" refers to the dried powder obtained by liquid fermentation of the asexual generation of the fungus *Cordyceps sinensis* (family Clavicipitaceae) isolated from the fruiting body of *Cordyceps sinensis*. In some contexts, it is equivalent to "fermented Cordyceps sinensis." For example, fermented Cordyceps sinensis mycelial powder can be the dried powder obtained by liquid fermentation of the asexual generation of the fungus *Cordyceps sinensis* (family Clavicipitaceae) isolated from fresh *Cordyceps sinensis* in Qinghai, or the dried powder obtained by liquid fermentation of the asexual generation of *Cordyceps sinensis* (family Clavicipitaceae) isolated from the fruiting body of *Cordyceps sinensis* in Tibet. In some embodiments, the fermented Cordyceps sinensis mycelial powder is derived from Bailin capsules, and its fingerprint profile matches that of wild Cordyceps sinensis, which is rich in nucleosides, sugar alcohols, sterols, and amino acids. Therefore, in terms of medicinal value, the two have similar effects. Because wild Cordyceps sinensis has a high heavy metal content, industrial fermentation processes are used to precisely control reaction conditions. This ensures that the metal content in the fermented Cordyceps sinensis powder meets safety standards and that the quality of each batch of product is stable and controllable, eliminating consumer concerns. At the same time, its price is far lower than that of wild Cordyceps sinensis.

[0113] Hangzhou Sino-American East China Pharmaceutical Co., Ltd. has exclusively produced a Class I new drug in China, "Bailing Capsules" (containing fermented Cordyceps sinensis mycelium powder CS-C-Q80), using artificial fermentation methods. This drug is listed in the Pharmacopoeia of the People's Republic of China. Cordyceps sinensis MBF1 mycelium powder (CS-C-Q80) is a dried powder of mycelium obtained from Hirsutella sinensis through deep liquid fermentation. Bailing Capsules can be used for cough, asthma, hemoptysis, lower back pain, facial puffiness, and frequent urination at night caused by deficiency of both lung and kidney; it is also used as an adjunct treatment for chronic bronchitis and chronic renal insufficiency.

[0114] In eukaryotes, gene transcription is regulated by a series of activators and repressors that recognize specific DNA sequences and interact with the minimal or basal transcription complex, influencing transcription initiation and efficiency. Multiprotein bridging factor 1 (MBF1) is a transcriptional coactivator first isolated from silkworms and subsequently found to be highly conserved in eukaryotes and archaea. The MBF1 from Cordyceps sinensis has the search code T5AE42 in the UniProt database (Universal Protein Resource, Uniprot: http: / / www.uniprot.org / ), and consists of 154 amino acids. Its amino acid sequence is as follows:

[0115] Its encoding base sequence is as follows:

[0116] In this article, the term "radiation injury to the hematopoietic system" refers to damage (or disease) to the hematopoietic system caused by exposure to a large dose (>1 Gy) of ionizing radiation in a short period of time, and the term "radiation injury to the intestines" refers to damage (or disease) to the intestines caused by exposure to a large dose (>1 Gy) of ionizing radiation in a short period of time.

[0117] In this document, "treatment" means: after contracting a disease, exposing (e.g., administering medication) the Cordyceps sinensis fermented mycelium extract (Cordyceps sinensis MBF1) described in this invention to a subject, thereby alleviating the symptoms of the disease compared to when not exposed, without implying the necessity of completely suppressing the symptoms of the disease. Contracting a disease means: the appearance of disease symptoms in the body.

[0118] In this article, "prevention" means that, before the onset of a disease, by exposing the subject to the Cordyceps sinensis fermentation mycelium extract (Cordyceps sinensis MBF1) described in this invention, the probability of contracting the disease and / or the symptoms after contracting the disease are reduced compared to when there is no exposure, and does not mean that it is necessary to completely suppress the disease.

[0119] The "subject" described in this invention can be a human or a non-human animal, or a cell, tissue, or organ of a human or non-human animal. The non-human animal can be a non-human mammal, including but not limited to wild animals, zoo animals, commercially valuable animals, pets, laboratory animals, etc. Preferably, the non-human mammal includes, but is not limited to, pigs, cattle, sheep, horses, donkeys, foxes, raccoon dogs, minks, camels, dogs, cats, rabbits, mice (e.g., rats, mice, guinea pigs, hamsters, gerbils, chinchillas, squirrels), or monkeys, etc.

[0120] The term "effective amount" as used in this invention refers to the amount or dose of Cordyceps sinensis of this invention that provides the desired treatment or prevention after being administered to a subject in one or more doses.

[0121] The present invention will be explained below with reference to embodiments. Those skilled in the art will understand that the following embodiments are for illustrative purposes only and should not be considered as limiting the scope of the invention. Where specific techniques or conditions are not specified in the embodiments, they are performed according to the techniques or conditions described in the literature in the field or according to the product instructions. Reagents or instruments whose manufacturers are not specified are all conventional products that can be obtained commercially.

[0122] Example 1: Functional application of water and alcohol extracts of fermented Cordyceps sinensis powder in preventing and treating radiation damage to the hematopoietic system.

[0123] The preparation method of fermented Cordyceps sinensis mycelium powder can be found in Example 1 of patent CN200710024324.9. Fermented Cordyceps sinensis mycelium powder can be used to prepare pharmaceuticals and / or health products, and can be made into different dosage forms such as tablets, capsules, granules, oral liquids, chewable tablets, effervescent tablets, and powders.

[0124] Physiological saline (0.9%) was purchased from Shandong Kelun Pharmaceutical Co., Ltd. 40 Exactor samples were purchased from Best Theratronics Ltd., Canada; the IL-6 detection kit was purchased from Shanghai Enzyme-Link Biotechnology Co., Ltd.; the experimental data analysis in the examples was performed using GraphPad Prisn 8 software, and the figures were generated.

[0125] Occludin: tight junction protein; IL-6: interleukin-6; IPTG: isopropyl mercapto-β-galactoside.

[0126] 1. Experimental animal groups: Male C57BL / 6J mice (6-8 weeks old, 19-21 grams, 6 mice per group) were randomly divided into five groups: simple irradiation group, alcohol extract prophylactic administration group, alcohol extract therapeutic administration group, water extract prophylactic administration group, and water extract therapeutic administration group.

[0127] 2. Model Building: Using Mice were subjected to whole-body gamma irradiation with 40Exactor at an absorbed dose of 4 Gy and a dose rate of 0.8 Gy / min. Following whole-body irradiation, the hematopoietic system of the mice was severely damaged, including hematopoietic organs such as the spleen and thymus.

[0128] 3. Extraction of components from fermented Cordyceps sinensis mycelium powder:

[0129] Aqueous extract extraction: Weigh 40g of Cordyceps sinensis fermented mycelium powder, add 1L of 95% ethanol, and sonicate for 1 hour using an ultrasonic homogenizer to remove lipids and pigments. Centrifuge at 12000g for 10 minutes to collect the precipitate. Then, redissolve the precipitate in 1L of distilled water, sonicate for 1 hour, centrifuge at 12000g for 10 minutes, collect the supernatant, concentrate the solution by freeze-drying, and dissolve in 50ml of physiological saline to obtain the aqueous extract of Cordyceps sinensis fermented mycelium powder.

[0130] Ethanol extraction: Weigh 40g of Cordyceps sinensis fermentation powder, add 1L of 95% ethanol, sonicate for 1 hour using an ultrasonic disruptor, centrifuge at 12000g for 10 minutes to collect the supernatant, concentrate the solution using vacuum centrifugation, add 50ml of physiological saline to make a suspension to obtain the ethanol extract of Cordyceps sinensis fermentation powder.

[0131] 4. Administration method and dosage:

[0132] The simple irradiation group: medication was started 7 days before irradiation and continued for 14 days after irradiation. The administration method was: normal saline was administered by gavage once a day at 10:00 am for 21 consecutive days. The gavage dose was 200 μL / animal / time.

[0133] Prophylactic administration of alcohol extract: Administration began 7 days before irradiation and continued for 14 days after irradiation. Administration method: oral administration of alcohol extract once a day at 10:00 am for 21 consecutive days; oral administration dose: 200 μL / animal / time.

[0134] Therapeutic administration of alcoholic extract: No medication was administered for 7 days before irradiation, and medication was started for 14 days after irradiation. Administration method: Alcoholic extract was administered by gavage once a day at 10:00 am for 14 consecutive days; Gavage dose: 200 μL / animal / time.

[0135] Prophylactic administration of aqueous extract: Administration began 7 days before irradiation and continued for 14 days after irradiation. Administration method: Aqueous extract was administered by gavage once a day at 10:00 am for 21 consecutive days. Gavage dose: 200 μL / animal / time.

[0136] Aqueous extract therapeutic drug group: No drug was administered for 7 days before irradiation, and drug was administered for 14 days after irradiation. The administration method was: aqueous extract was administered by gavage once a day at 10:00 am for 14 consecutive days; the gavage dose was 200 μL / animal / time.

[0137] 5. Observation indicators: Due to the severe damage to the hematopoietic system of mice caused by whole-body irradiation, namely a decrease in the number of peripheral blood white blood cells and a decrease in the hematopoietic organ index, mice were anesthetized with chloral hydrate and euthanized on day 21. Whole blood was collected from the orbital fossa, and the white blood cell count was measured using a blood count analyzer. The mice were dissected, and the spleen and thymus, the two main hematopoietic organs, were harvested. The weights of the thymus and spleen, as well as the final body weight of the mice, were measured, and the spleen index (spleen weight / body weight) and thymus index (thymus weight / body weight) were calculated.

[0138] 6. Results and Conclusions: The results are shown in Table 1 and Figures 1-3. Compared with the control group, the white blood cell count, spleen index, and thymus index were not increased in the prophylactic and therapeutic groups of the ethanol extract. In the prophylactic group of the aqueous extract, the white blood cell count was significantly increased (p<0.01), the spleen index was significantly increased (p<0.05), and the thymus index was not increased. In the therapeutic group of the aqueous extract, the white blood cell count was significantly increased (p<0.001), the spleen index was significantly increased (p<0.01), and the thymus index was significantly increased (p<0.05). Therefore, the aqueous extract of Cordyceps sinensis MBF1 can repair hematopoietic system damage caused by ionizing radiation, and the therapeutic effect is significantly better than the preventive effect. The ethanol extract showed no significant preventive or therapeutic effects.

[0139] Table 1. Hematopoietic system status of mice in the experimental group (values ​​are within-group means)

[0140] Example 2: Functional application of Cordyceps sinensis mycelium powder aqueous extract in the treatment of intestinal radiation injury

[0141] 1. Experimental animal groups: Male C57BL / 6J mice (6-8 weeks old, 19-21 grams, 6 mice per group) were randomly divided into three groups: blank group, irradiation group, and water extract therapeutic drug group.

[0142] 2. Model Building: Using 40 Exactor irradiated the entire abdomen of mice with gamma rays to the abdominal area ( The 40 Exactor comes with a local irradiation mold, exposing the entire abdomen, with an absorbed dose of 13 Gy and a dose rate of 0.8 Gy / min.

[0143] 3. Component extraction is the same as in Example 1.

[0144] 4. Administration method and dosage:

[0145] Control group: No irradiation was received. Administration method: normal saline was administered by gavage once a day at 10:00 am for 14 consecutive days; gavage dose: 200 μL / animal / time.

[0146] Irradiation-only group: Drug administration started on the day of irradiation. Administration method: normal saline was administered by gavage once a day at 10:00 am for 14 consecutive days. Gavage dose: 200 μL / animal / time.

[0147] Aqueous extract therapeutic drug group: Drug administration started on the day of irradiation. Administration method: Aqueous extract was administered by gavage once a day at 10:00 am for 14 consecutive days. Gavage dose: 200 μL / animal / time.

[0148] 5. Observation indicators: Due to the severe damage to the colon and small intestine of mice caused by local abdominal irradiation, namely shortened colon length, disruption of small intestinal wall integrity, and increased inflammation level, mice were anesthetized with chloral hydrate and euthanized on day 14. The mice were then dissected, and the colon length was measured. The expression level of the small intestinal wall integrity marker gene Occludin and the content of the inflammatory factor IL-6 were also determined.

[0149] Method for determining the expression level of Occludin, a marker gene for small intestinal wall integrity: On day 14, mice were anesthetized with chloral hydrate and euthanized. Small intestinal tissue was dissected and 0.1g of the tissue was placed in a sterile, enzyme-free EP tube. 1mL of Trizol solution was added, and the tissue was rapidly homogenized in a tissue homogenizer. The mixture was incubated at room temperature for 10 min to fully lyse the cells. 0.2mL of chloroform was added, and the mixture was vigorously shaken for 30 seconds. After mixing, the mixture was allowed to stand at room temperature for 10 min. The mixture was then centrifuged at 12000rpm for 15 min at 4℃, and the supernatant was collected into a fresh, sterile container. Add 0.5 mL of isopropanol to a sterile, enzyme-free EP tube, mix well, and let stand at room temperature for 10 min; centrifuge at 12000 rpm for 15 min at 4 °C, and discard the supernatant; add 1 mL of 75% ethanol to wash the RNA, centrifuge at 12000 rpm for 10 min at 4 °C, discard the supernatant, dry at room temperature, and add 100 μL of sterile, enzyme-free water to dissolve the RNA precipitate; synthesize cDNA using a cDNA reverse transcription kit (TransGold, China), and detect the expression level of the mouse Occludin gene by real-time PCR.

[0150] The IL-6 content in the small intestine of mice was detected using an IL-6 assay kit. The method was as follows: On day 14, mice were anesthetized with chloral hydrate and euthanized. The mice were dissected, and small intestinal tissue was collected. The tissue was added to an appropriate amount of physiological saline (1 ml of physiological saline for 0.1 g of tissue) and homogenized. The mixture was centrifuged at 3000 g / min for 20 minutes, and the supernatant was collected. The sample was diluted 1:1 with sample diluent and 50 μL was added to each well. 50 μL of diluted standard and 50 μL of the test sample were added to each well. Immediately, 50 μL of biotin-labeled antibody was added. The plate was covered, gently vortexed to mix, and incubated at 37°C for 1 hour. The liquid in the wells was discarded, and each well was filled with washing buffer, vortexed for 30 seconds, discarded, and patted dry with absorbent paper. This process was repeated 3 times. If a plate washer was used, the number of washes was increased by one. 80 μL of avidin-HRP was added to each well, gently vortexed to mix, and incubated at 37°C for 30 minutes. Discard the liquid from the wells, fill each well with washing buffer, shake for 30 seconds, discard the washing buffer, and pat dry with absorbent paper. Repeat this operation 3 times. If using a plate washer, increase the number of washes by one. Add 50 μL each of substrate A and B to each well, gently shake to mix, and incubate at 37°C for 10 minutes. Avoid light exposure. Remove the microplate and quickly add 50 μL of stop solution. Measure the results immediately after adding the stop solution. Measure the OD value of each well at 450 nm. Plot the absorbance (OD value) on the ordinate (Y) and the corresponding concentration of the analyte standard on the abscissa (X) to create a curve. The concentration of the analyte in the sample can be calculated from the standard curve based on its OD value.

[0151] 6. Results and Conclusions: The results are shown in Table 2 and Figures 4-6. Compared with the control group, after local abdominal irradiation with gamma rays, the colon length of the irradiation-only group was significantly shortened (p<0.01), the expression level of the small intestinal wall integrity marker gene Occludin was significantly decreased (p<0.05), and the content of the small intestinal inflammatory factor IL-6 was significantly increased (p<0.05). However, compared with the irradiation-only group, continuous gavage administration of Cordyceps sinensis mycelium extract for 14 days significantly improved colonic injury, small intestinal wall integrity damage, and inflammation levels in mice. Specifically, the colon length of the therapeutically administered group was longer (p<0.05), the expression level of the small intestinal wall integrity marker gene Occludin was significantly increased (p<0.001), even exceeding that of the control group, and the content of the inflammatory factor IL-6 in the small intestine was significantly decreased (p<0.001), even lower than that of the control group. Therefore, Cordyceps sinensis MBF1 aqueous extract can effectively treat intestinal damage caused by ionizing radiation.

[0152] Table 2. Intestinal condition of mice in the experimental group of Example 2 (values ​​are within-group mean)

[0153] Example 3: Functional application of Cordyceps sinensis mycelium powder protein polysaccharide component in the treatment of intestinal radiation injury

[0154] 1. Experimental animal groups: Male C57BL / 6J mice (6-8 weeks old, 19-21 grams, 6 mice per group) were randomly divided into three groups: blank group, irradiation group, and water extract therapeutic drug group.

[0155] 2. Model Building: Using 40 Exactor irradiated the entire abdomen of mice with gamma rays to the abdominal area ( The 40 Exactor comes with a local irradiation mold, exposing the entire abdomen, with an absorbed dose of 13 Gy and a dose rate of 0.8 Gy / min.

[0156] 3. Extraction of polysaccharide and protein components:

[0157] Polysaccharide extraction: The aqueous extract of Cordyceps sinensis mycelium powder was extracted in the same manner as in Example 1. The aqueous extract was concentrated to 200 ml by freeze drying. 800 ml of anhydrous ethanol was added to the aqueous extract, and the mixture was incubated overnight at 4°C to allow the polysaccharides to fully precipitate. The mixture was then centrifuged at 5000 g for 10 min to precipitate the polysaccharides. The polysaccharide precipitate was dissolved in 16 ml of distilled water, and 4 ml of Sevag solution (chloroform: n-butanol = 4:1, v / v) was added to remove the protein. The mixture was shaken thoroughly for 30 min, centrifuged at 5000 g for 1 min, and the supernatant was collected. The supernatant was dialyzed in distilled water (molecular weight cutoff of 8000 Da) for 2 days. The dialyzed solution was then freeze-dried to obtain the crude Cordyceps sinensis polysaccharide powder.

[0158] Protein extraction: The aqueous extract of Cordyceps sinensis mycelium powder was extracted in the same manner as in Example 1. The solution was concentrated to 200 ml by freeze drying. Solid ammonium sulfate was added until its saturation reached 40%-80%. The solution was allowed to stand on ice for 1 hour, and then centrifuged at 12000 g and 4°C for 30 min to collect the protein precipitate. The protein precipitate was dissolved in 20 ml of pre-cooled PBS buffer solution at pH 7.4. The protein was then dialyzed overnight in PBS solution at 4°C (molecular weight cutoff of 8000 Da) to remove ammonium sulfate. The solution was concentrated by freeze drying to obtain crude protein powder.

[0159] 4. Administration method and dosage:

[0160] Irradiation-only group: Drug administration began on the day of irradiation. Administration method: normal saline was administered by gavage once a day at 10:00 am for 14 consecutive days. Gavage dose: 20 mg / animal / time.

[0161] Polysaccharide therapeutic drug administration group: Drug administration started on the day of irradiation. Administration method: polysaccharide was administered by gavage once a day at 10:00 am for 14 consecutive days. Gavage dose: 20mg / animal / time.

[0162] Protein therapeutic drug group: Drug administration started on the day of irradiation. Administration method: protein was administered by gavage once a day at 10:00 am for 14 consecutive days. Gavage dose: 20mg / animal / time.

[0163] 5. The observation indicators are the same as in Example 2.

[0164] 6. Results and Conclusions: The results are shown in Figures 3 and 7-9. Compared with the irradiation-only group, continuous gavage administration of Cordyceps sinensis protein for 14 days significantly improved colonic injury, small intestinal wall integrity damage, and inflammation levels in mice. Specifically, the colon length in the protein-treated group was increased (p<0.01), the expression level of the small intestinal wall integrity marker gene Occludin was significantly increased (p<0.001), and the content of the inflammatory factor IL-6 in the small intestine was significantly decreased (p<0.001). However, continuous gavage administration of Cordyceps sinensis polysaccharide for 14 days did not significantly improve colonic injury and small intestinal wall integrity damage in mice, although the inflammation level was reduced to some extent (p<0.05). Therefore, Cordyceps sinensis protein components can effectively treat intestinal damage caused by ionizing radiation.

[0165] Table 3. Intestinal condition of mice in the experimental group of Example 3 (values ​​are within-group mean)

[0166] Example 4: Functional Application of Cordyceps Sinensis T5AE42 in Treating Intestinal Radiation Injury

[0167] 1. Experimental animal groups: Male C57BL / 6J mice (6-8 weeks old, 19-21 grams, 6 mice per group) were randomly divided into two groups: the irradiation group and the T5AE42 protein therapeutic administration group.

[0168] 2. Model Building: Using 40 Exactor irradiated the entire abdomen of mice with gamma rays to the abdominal area ( The 40 Exactor comes with a local irradiation mold, exposing the entire abdomen, with an absorbed dose of 13 Gy and a dose rate of 0.8 Gy / min.

[0169] 3. Identification of protein components and heterologous expression in E. coli:

[0170] The crude protein powder prepared in Example 3 was subjected to mass spectrometry identification, and the six most abundant proteins were identified as T5ANN4, T5A8F6, T5AE42, T5AEN3, T5AAF5, and T5AAQ0 (these protein names are protein search codes in the UniProt database). The crude protein powder was dissolved and subjected to SDS-PAGE electrophoresis, as shown in Figure 10. The peptide identification results of T5AE42 protein by mass spectrometry are shown in Figure 15. After comparison with the UniProt database, it was found that only T5AE42 among the six proteins was a functional protein, a transcriptional coactivator.

[0171] Identification of crude protein components:

[0172] S1: The crude protein powder was subjected to SDS-PAGE gel electrophoresis. The protein gel strips were cut into small cubes, washed with water, and then incubated with destaining solution (50mM TEAB and 50% acetonitrile) until complete destaining. Then, 50mM TEAB buffer was added for three consecutive washes. Acetonitrile was added to dehydrate the gel particles until completely white, and the mixture was air-dried. 10mM DTT was added and reacted at 56℃ for 40 min. After washing with destaining solution, acetonitrile was added again for dehydration until completely white, and the mixture was air-dried. 50mM IAM was added and reacted at room temperature in the dark for 0.5 h. After washing with destaining solution, acetonitrile was added again for dehydration until completely white, and the mixture was air-dried.

[0173] S2: Add 100mM TEAB buffer and 1μg trypsin to the gel particles, then add 1 / 300 CaCl2 and digest overnight at 37℃. Collect the supernatant by low-speed centrifugation, add acetonitrile to the gel particles, vortex and centrifuge, collect the supernatant, add 0.1% formic acid to the gel, shake at room temperature for 5 min, then centrifuge at low speed to collect the supernatant, combine the supernatants and freeze-dry. Reconstitute with 0.1% formic acid aqueous solution, mix well, centrifuge at 12000g for 5 min at room temperature, collect the supernatant and slowly pass it through a C18 desalting column, then wash three times consecutively with washing buffer (0.1% formic acid, 3% acetonitrile), then add an appropriate amount of elution buffer (0.1% formic acid, 70% acetonitrile), collect the filtrate, and freeze-dry.

[0174] S3: Prepare mobile phases A (100% water, 0.1% formic acid) and B (80% acetonitrile, 0.1% formic acid). Dissolve the lyophilized powder in 10 μL of mobile phase A, centrifuge at 14000g for 20 min at 4℃, and inject 1 μg of the supernatant sample for LC-MS analysis. Use an EASY nLC™ 1200 nano-scale UHPLC system with a self-made pre-column (4.5cm × 75μm, 3μm) heated in a 55℃ column oven. Use a self-made analytical column (25cm × 150μm, 1.9μm). An Orbitrap Exploris 480 (with FAIMS) mass spectrometer and Nanospray Flex were used. TM The (ESI) ion source was set to an ion spray voltage of 2.1 kV and an ion transmission tube temperature of 320 °C. The mass spectrometry employed a data-dependent acquisition mode. The FAIMS compensation voltages were set to -45 and -65 kV, with the same acquisition parameters used for both voltages. The full scan range of the mass spectrometer was [m / z]. The mass spectrometry resolution was set to 60000 (200 m / z) for the first-stage mass spectrometry range of 350-1500, with a maximum C-trap capacity of 3 × 10⁶ and a maximum C-trap injection time set to Auto. This maintained maximum sensitivity while simultaneously increasing the scan rate to automatically calculate the ion implantation time. The second-stage cyclic scan time was 1 s. Within 1 s, high-energy collisional fragmentation (HCD) was used to select as many precursor ions as possible from high to low response intensity in the first-stage scan for fragmentation. The second-stage mass spectrometry resolution was set to 15000 (200 m / z), with a maximum C-trap capacity of 7.5 × 10⁴, a maximum C-trap injection time of 22 ms, a peptide fragmentation collision energy of 30%, a threshold intensity of 5.0 × 10³, and a dynamic exclusion range of 40 s. Raw mass spectrometry data were generated. Proteome Discoverer 2.4 (PD2.4, Thermo) was used to search all resulting spectra.

[0175] Construction and identification of genetically engineered bacteria expressing T5AE42 protein:

[0176] S1: The nucleotide sequence shown in SEQ ID NO:2 was artificially synthesized (commissioned to Suzhou Genewise Biotechnology Co., Ltd.) to obtain the T5AE42 protein encoding gene;

[0177] S2: The T5AE42 protein encoding gene and pET32M plasmid vector (purchased from Suzhou Genewise Biotechnology Co., Ltd.) were digested with EcoRI and BamHI, and the digestion products were recovered by gel extraction.

[0178] S3: The digestion product was ligated with T4 ligase (the schematic diagram of the pET32M-T5AE42 recombinant plasmid is shown in Figure 11), and the ligation product was transformed into BL21(DE3) host Escherichia coli (BL21(DE3) host Escherichia coli was purchased from Suzhou Genewise Biotechnology Co., Ltd.);

[0179] S4: Pick a single colony and inoculate it into a test tube containing LB liquid medium. Incubate at 37°C and 220 rpm for 12 h; extract the recombinant plasmid.

[0180] S5: Perform enzyme digestion verification and sequence verification of the pET32M-T5AE42 recombinant plasmid (the sequencing was sent to Suzhou Genewise Biotechnology Co., Ltd. The sequencing results showed that the strain with the complete recombinant gene sequence was the strain carrying the T5AE42 protein encoding gene recombinant plasmid). Select the strain with the correct T5AE42 protein encoding gene, which is the genetically engineered bacterium expressing the T5AE42 protein.

[0181] Inducible expression of T5AE42 protein:

[0182] S1: Inoculate the selected genetically engineered bacteria into LB plates containing 100 mg / L ampicillin and culture at 37°C for 14-18 h;

[0183] S2: Pick a single colony and place it into LB medium containing 80 mg / L kanamycin. Incubate at 37°C and 250 rpm for 10-15 h to form a seed culture.

[0184] S3: Transfer the seed culture at an inoculum of 5% to LB medium containing 100 mg / L ampicillin, and incubate at 37°C and 250 rpm until the OD600nm is 1.5;

[0185] S4: Add IPTG to a final concentration of 0.3 mmol / L and induce fermentation at 23℃. After 5 hours of induction, stop fermentation. The fermentation broth is the N-deoxyribonuclease solution. Centrifuge at 5000 rpm for 10 minutes and collect the bacterial cells. At this point, the bacterial cells contain the target protein T5AE42.

[0186] S5: Since T5AE42 carries a His tag, the T5AE42 protein can be purified in large quantities using a His-tagged protein purification kit (Beyotime, China).

[0187] 4. Administration method and dosage:

[0188] Irradiation-only group: Drug administration started on the day of irradiation. Administration method: normal saline was administered by gavage once a day at 10:00 am for 14 consecutive days. Gavage dose: 200 μL / animal / time.

[0189] The T5AE42 protein therapeutic administration group: The administration began on the day of irradiation. The administration method was: T5AE42 protein PBS solution was administered by gavage once a day at 10:00 am for 14 consecutive days. The gavage dose was 20 μg / animal / time, with 20 μg of T5AE42 protein dissolved in 200 μL of PBS solution.

[0190] 5. The observation indicators are the same as in Example 2.

[0191] 6. Results and conclusions: The results are shown in Table 4 and Figures 12-14.

[0192] Table 4. Intestinal condition of mice in the experimental group of Example 4 (values ​​are within-group mean)

[0193] Compared with the irradiation-only group, continuous gavage administration of T5AE42 protein for 14 days significantly improved colonic injury, small intestinal wall integrity damage, and inflammation levels in mice. Specifically, the T5AE42 protein treatment group showed increased colonic length (p<0.001), significantly increased expression of the small intestinal wall integrity marker gene Occludin (p<0.001), and significantly decreased levels of the inflammatory cytokine IL-6 in the small intestine (p<0.001). This demonstrates that T5AE42 protein, as a transcriptional coactivator, can effectively treat intestinal damage induced by ionizing radiation.

Claims

1. Use of Cordyceps sinensis MBF1 in the preparation of products for the prevention and / or treatment of radiation damage.

2. The use according to claim 1, characterized in that, The radiation damage is caused by ionizing radiation.

3. The use according to claim 2, characterized in that, The ionizing radiation mentioned is the ionizing radiation generated by tumor radiotherapy.

4. The use according to claim 3, characterized in that, The ionizing radiation is gamma-ray radiation.

5. The use according to any one of claims 1 to 4, characterized in that, The radiation damage is intestinal radiation damage and / or hematopoietic system radiation damage.

6. The use according to claim 5, characterized in that, The intestinal type radiation injury has one or more of the following symptoms: shortened colon length, small intestinal tissue damage, and elevated level of small intestinal inflammation; Radiation injury to the hematopoietic system presents with one or more of the following symptoms: decreased white blood cell count, decreased spleen index, and / or decreased thymus index.

7. The use according to claim 6, characterized in that, The marker of small intestinal tissue damage is a decrease in the expression level of the small intestinal Occludin gene.

8. The use according to claim 6, characterized in that, The elevated level of small intestinal inflammation includes an increase in the level of inflammatory immune factors.

9. The use according to claim 8, characterized in that, The inflammatory immune factor is IL-6.

10. The use according to any one of claims 1 to 9, characterized in that, The amino acid sequence of the Cordyceps sinensis MBF1 contains SEQ ID NO: 1, or contains an amino acid sequence that has at least 90% homology with the sequence shown in SEQ ID NO:

1.

11. The use according to claim 10, characterized in that, The amino acid sequence of the Cordyceps sinensis MBF1 is shown in SEQ ID NO:

1. Use of 12.4mg to 8mg unit dose of Cordyceps sinensis MBF1 in products for the prevention and / or treatment of radiation damage: The unit dose of Cordyceps sinensis MBF1 is administered once daily.

13. The use according to claim 12, characterized in that, The radiation damage is caused by ionizing radiation.

14. The use according to claim 13, characterized in that, The ionizing radiation mentioned is the ionizing radiation generated by tumor radiotherapy.

15. The use according to claim 14, characterized in that, The ionizing radiation is gamma-ray radiation.

16. The use according to any one of claims 12 to 15, characterized in that, The radiation damage is intestinal radiation damage and / or hematopoietic system radiation damage.

17. The use according to claim 16, characterized in that, The intestinal type radiation injury has one or more of the following symptoms: shortened colon length, small intestinal tissue damage, and elevated level of small intestinal inflammation; Radiation injury to the hematopoietic system presents with one or more of the following symptoms: decreased white blood cell count, decreased spleen index, and / or decreased thymus index.

18. The use according to claim 17, characterized in that, The marker of small intestinal tissue damage is a decrease in the expression level of the small intestinal Occludin gene.

19. The use according to claim 17, characterized in that, The elevated level of small intestinal inflammation includes an increase in the expression of inflammatory immune factors.

20. The use according to claim 19, characterized in that, The inflammatory immune factor is IL-6.

21. Use of a Cordyceps sinensis containing MBF1 in the preparation of products for the prevention and / or treatment of radiation damage.

22. The use according to claim 21, characterized in that, The radiation damage is intestinal radiation damage and / or hematopoietic system radiation damage.

23. The use according to any one of claims 1 to 22, characterized in that, The product in question is a health supplement or a medicine.

Images